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ABSTRACT
Objectives: Novel isoxazole incorporated pyrazole carbothiamide 5 (a-r) was designed and synthesized, docked and evaluated for anticancer activity 
Michigan Cancer Foundation-7 (MCF-7), and breast cancer cell lines.
Materials and Methods: Designed compounds were synthesized by the condensation of 1-(5-methyl-3-(4-nitrophenyl) isoxazole-4-yl) -3-(substitutedphenyl) 
prop-2-en-1-one (4) with thiosemicarbazides and substituted thiosemicarbazides to give the target molecules 5 (a-r). To predict the affinity and activity of 
the ligand molecule, the docking program Accelrys Discovery Studio 2.1 was employed to generate different bioactive binding poses of designing molecules 
at the active site of human Dihydrofolate Reductase (DHFR) (PDB ID: 1KMS). All the synthesized compounds were characterized based on the spectral and 
elemental analysis data. Antiproliferative activity was performed against MCF-7 breast cancer cell lines.
Results: All the synthesized compounds showed the characteristic peaks in Fourier-transform infrared,1H C13NMR, and mass spectral analysis. 
During docking, all the synthesized compounds 5 (a-r) exhibited higher fitness scores with minimum three bonding interaction with the active site 
human DHFR (PDB ID: 1KMS). In the MTT assay based on MCF-7 breast cancer cell lines, most of the compounds exhibited significant activity. In 
the antiproliferative assay against MCF-7 cell lines, most of the compounds exhibited potent activity with IC50 values in micromolar concentrations. 
Compounds 5a, 5b, 5f, 5h, and 5k have exhibited significant anticancer activity.
Conclusions: The derivatives were synthesized in quantitative yields. New derivatives possess the antiproliferative activity.
Keywords: Isoxazole, Pyrazole, Carbothiamide, Antiproliferative activity.
INTRODUCTION
Cancer [1] is projected as one of the second most prevalent types of 
all diseases responsible for mortality overall the world. Interrupting 
the folate metabolism in cancerous cells may accommodate a 
favorable chance in cancer chemotherapy as a consequence of the 
inhibition of the biosynthesis of nucleic acid precursors. Thus, an 
inhibitor of the DHFR enzyme in cancerous cells would result in the 
inhibition of tetrahydrofolate synthesis; consequently, the nucleic 
acid precursors [2-4]. Isoxazoles and pyrazoles were used widely 
for the pharma world. Pyrazoles are used as anti-inflammatory [5], 
antioxidant [6], anticonvulsant [7], anticancer [8], antimicrobial [9,10], 
antiviral [11], and wide range of activities [12]. On the other hand, 
isoxazoles possess an extensive lineup of biological activities as well as 
forming an integrate of varied biodynamic agents [13,14]. A number of 
isoxazoles and related compounds are known to exhibit antitumor [15], 
anti-HIV [16], anti-inflammatory [17], antioxidant [18], antiviral [19], 
and antimicrobial activities [20]. Various biological activities of pyrazoles 
and isoxazole pharmacophores led to the search for new bioactive 
compounds of this class [21]. In the present study, while designing target 
molecules, isoxazole heterocycle is condensed with thiosemicarbazide 
to obtain pyrazole-1-carbothiamide incorporated isoxazole scaffold to 
obtain new hybrid molecules. Further, the designed molecules were 
computationally docked into target human DHFR (PDB ID: 1KMS) 
using an Accelrys discovery studio to gain some structural insights 
into the binding mode of designing molecules. The compounds that 
demonstrated a high fitness score in comparison with the reference 
drug, doxorubicin and are further planned to screen anti-proliferation 




All the chemicals and solvents used were of synthetic grade from SD 
Fine Chemicals Ltd., (Mumbai, India), and Avra Chemicals Pvt. Ltd., 
Hyderabad. Completion of the reactions was monitored by analytical 
thin-layer chromatography (TLC) using E-Merck 0.25 mm silica gel 
plates. Visualization was accomplished with ultraviolet light (256 nm) 
and iodine chamber. Synthesized compounds were purified by a 
recrystallization process. The purity of the compounds was checked by 
a single spot in TLC and a solvent system for TLC was determined on 
trial and error basis. Melting points were determined in open capillary 
tubes using ANALAB melting point apparatus and were uncorrected. All 
the 1H NMR spectra were recorded on Varian 400 MHz spectrometer 
using CDCl3 as solvent and tetramethyl silane as an internal standard. 
Chemical shift values are listed in δ scale. The Fourier-transform infrared 
(FT-IR) spectra were recorded on Shimadzu FT-IR spectrophotometer 
using 1% potassium bromide discs. Mass spectra of the compounds 
were recorded on electronic ionization mass spectra on Agilent 1100 
series.
Synthesis of 4-nitrobenzaldehyde oxime (1)
4-nitrobenzaldehyde (0.01 mmol) was placed in a RBF containing 
10 ml of ethanol. To the above mixture hydroxylamine hydrochloride 
(0.02 mmol) and anhydrous sodium acetate (0.02 mmol) were 
added with constant stirring and reflux for 3–4 h. The reaction was 
monitored by TLC. The resulting solution was poured into crushed 
ice. The obtained precipitate was filtered and thoroughly washed 
with water and air dried. TLC solvent systems – pet. ether:ethyl 
acetate (70:30).
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i5.32591
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Synthesis of N-hydroxy-4-nitrobenzimidoyl chloride (2)
4-Nitrobenzaldehyde oxime (0.01 mmol) and N-Chlorosuccinamide 
(0.01 mmol) were dissolved in dimethylformamide then it was stirred 
for overnight at room temperature. The reaction was monitored by 
TLC. After completion of the reaction, solution was poured into ice cold 
water. The obtained precipitate was filtered and washed thoroughly 
with ice cold water and air dried. TLC solvent systems – pet. ether:ethyl 
acetate (70:30).
Synthesis of 1-(5-methyl-3-(4-nitrophenyl) isoxazol-4-yl) 
ethanone (3)
To the sodium hydroxide (0.02 mol) in methanol, acetylacetone 
(0.04 mmol) was added and maintained at 0-5°C and stirred for 10–15 min 
by maintaining pH 10. To this mixture 0.02 mmol, aryl oxime was added 
and stirred on a magnetic stirrer for 1–2 h. The completion of the reaction 
was monitored by TLC. After the completion of the reaction, the reaction 
mixture was poured into crushed ice. The precipitate was filtered and 
dried in air. TLC solvent systems – pet. ether:ethyl acetate (70:30).
Synthesis of 1-(5-methyl-3-(4-nitrophenyl) isoxazol-4-yl) 
-3-(substituted phenyl) prop-2-en-1-one (4)
An equimolar quantity of isoxazole ketone (0.01 mmol) and substituted 
aryl aldehyde (0.01 mmol) were dissolved in 15–20 ml of alcohol in it 
NaOH (10%) added and stirred on magnetic stirrer over a period of 
30 min to 1 h. The reaction was monitored by TLC. The formed solid was 
filtered, washed with alcohol and dried in air. TLC solvent systems – pet. 
ether:ethyl acetate (70:30).
Synthesis of 5-(substituted phenyl) -3-(5-methyl-3-(4-nitrophenyl) 
isoxazol-4-yl) -4,5-dihydro-1H-pyrazole-1-carbothioamide and 
5-(substituted phenyl) -N-methyl-3-(5-methyl-3-(4-nitrophenyl) 
isoxazol-4-yl) -4,5-dihydro-1H-pyrazole-1-carbothioamide5 (a-r)
The intermediate 4 (a-m) (0.001 mol), thiosemicarbazide and 
substituted thiosemicarbazide (0.001 mmol) were taken into R.B.F 
containing ethanol to it, KOH (10%) solution was added refluxed for 
2 h. The completion of the reaction was monitored by TLC. The reaction 
mixture was poured into crushed ice to obtain a solid product. Then, 
the precipitate was filtered under suction, washed thoroughly with 
water and recrystallized from aqueous methanol. Purity and structural 
confirmation were done by mp and infrared (IR) spectrum. TLC solvent 




Yield 70%, mp 121–128°C. IR spectrum, ν, cm-1: 3337, 2928, 1520, 
1348, 1404, 1095, 1030. 1H NMR (400 MHz, DMSO-d6) δ 2.60 (s, 3H, 
CH3), 3.0 (dd, 1H, CH2), 3.9 (dd, 1H, CH2), 6.0 (td, 1H, -CH), 7.00–7.31 
(m, 4H, ArH), 7.6 (s, 1H, NH2), 7.8–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2). 
 Fig. 1: Scheme for the synthesis of 5-(4-Substitutedphenyl)-3-(5-methyl-3-(4-nitrophenyl) isoxazole-4-yl)-4,5-dihydro-1H-pyrazole-1-
carbothioamide/N-1-carbothiamides
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13C NMR (100 MHz, DMSO-d6) δ 171.2, 168.3, 162.3, 158.9, 152.2, 
148.5, 138.3, 134.4, 127.5, 127.0, 125.2, 118.7, 109.7, 62.6, 56.8, 42.3, 
13.1.ESI-MS: m/z438 (M+1) observed for C21H19N5O3S.
5-(4-chlorophenyl)-3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-
4,5-dihydro-1H-pyrazole-1-carbothioamide (5b)
Yield 71%, mp 104–112°C. IR spectrum, ν, cm−1: 3349, 2922, 1520, 
1348, 1404, 1096, 750. 1H NMR (400 MHz, DMSO-d6) δ 2.6 (s, 3H, CH3), 
3.1 (dd, 1H, CH2), 3.9 (dd, 1H, CH2), 6.0 (td, 1H, -CH), 7.2–7.4 (m,4H,ArH), 
7.6 (d, 2H, ArH), 7.9 (s, 1H, NH2), 7.9–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2). 
13CNMR (100MHz,DMSOd6) δ172.3, 169.8, 158.8, 152.1, 148.8, 138.6, 
134.1, 132.8, 128.6, 127.9, 126.2, 124.8, 105.9, 62.8, 42.3, 13.3. ESI-
MS: m/z443 (M+1) observed for C20H16ClN5O3S.
3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-5-phenyl-4,5-
dihydro-1H-pyrazole-1-carbothioamide (5c)
Yield 69%, mp 119–125°C. IR spectrum, ν, cm−1: 3337, 2924, 1629, 1520, 
1404, 1348, 1095. 1H NMR (400 MHz, DMSO-d6) δ 2.7 (s, 3H, CH3), 3.0 
(dd, 1H, CH2), 3.9 (dd, 1H, CH2), 5.9 (td, 1H, -CH), 7.1–7.4 (m, 5H, ArH), 
7.6 (d,2H,ArH), 7.7 (s, 1H, NH2), 7.9–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2). 
13CNMR (100MHz,DMSOd6) δ 171.9, 169.2, 158.8, 152.2, 148.6, 140.9, 
134.9, 128.4, 126.9, 126.2, 124.9, 123.5, 109.8, 62.4, 42.6, 13.0.ESI-MS: 
m/z408 (M+1) observed for C20H17N5O3S.
5-(4-bromophenyl)-3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-
4,5-dihydro-1H-pyrazole-1-carbothioamide (5d)
yield 70%, mp 117–124°C. IR spectrum, ν, cm−1:3349, 2929, 1520, 
1348, 1404, 1240, 1095, 668. 1H NMR (400 MHz, DMSO-d6) δ 2.8 
(s, 3H, CH3), 3.1 (dd, 1H,CH2), 4.1 (dd, 1H, CH2), 5.9 (td, 1H, CH), 7.1–
7.5 (m,4H,ArH), 7.7 (s,1H,NH2), 7.8–8.1 (m,4H,ArH), 8.2 (s,1H,NH2). 
13CNMR (100MHz,DMSOd6) δ 171.9, 169.4, 158.9, 152.5, 148.2, 141.2, 
136.4, 130.2, 127.8, 126.8, 126.4, 124.7, 105.8, 62.6, 42.1, 13.4. ESI-MS: 
m/z486 (M+1) observed for C20H16 BrN5O3S.
3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-5-(p-tolyl)-4,5-
dihydro-1H-pyrazole-1-carbothioamide (5e)
Yield 72%, mp 125–137°C. IR spectrum, ν, cm−1:3346, 2923, 1520, 
1404 1348, 1095. 1H NMR (400 MHz, DMSO-d6) δ 2.6 (s, 3H, CH3), 2.8 
(s, 3H, CH3), 3.2 (dd, 1H, CH2), 4.0 (dd, 1H, CH2), 6.0 (td, 1H, -CH), 7.1–7.4 
(m, 4H, ArH), 7.6 (s, 1H, NH2), 7.9–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2). 
13C NMR (100 MHz, DMSO-d6) δ171.8, 169.4, 158.4, 152.8, 148.2, 138.1, 
136.6, 134.8, 128.5, 126.4, 125.1, 123.3, 109.5, 62.4, 42.4, 21.5, 13.1. 
ESI-MS: m/z 422 (M+1) observed for C21H19N5O3S.
5-(4-fluorophenyl)-3-(5-methyl-3-(4-nitrophenyl) isoxazol-4-yl)-
4,5-dihydro-1H-pyrazole-1-carbothioamide (5f)
Yield 70%, mp 110–116°C. IR spectrum, ν, cm−1: 3349, 2993, 1520, 
1404, 1348, 1095, 1000. 1H NMR (400 MHz, DMSO-d6) δ 2.7 (s, 3H, CH3), 
3.0 (dd, 1H, CH2), 3.9 (dd, 1H, CH2), 5.9 (td, 1H, -CH), 7.2–7.5 (m, 4H, 
ArH), 7.7 (s, 1H, NH2), 7.8–8.0 (m, 4H, ArH), 8.2 (s, 1H, NH2). ESI-MS: m/
z426 (M+1) observed for C20H16 FN5O3S. 13C NMR (100 MHz, DMSO-d6) 
δ 172.2, 169.5, 161.1, 158.8,152.3, 148.5, 138.7, 134.6, 128.9, 126.7, 




Yield 69%, mp 96–108°C. IR spectrum, ν, cm−1: 3346, 2925, 1520, 1404, 
1348, 1095, 750. 1H NMR (400 MHz, DMSO-d6) δ 2.7 (s, 3H, CH3), 3.0 
(dd, 1H, CH2), 4.0 (dd, 1H, CH2), 5.9 (td, 1H, -CH), 7.2–7.5 (m, 4H, ArH), 
7.7 (s, 1H, NH2), 7.8–8.1(m, 4H, ArH), 8.2 (s, 1H, NH2). 13C NMR (100 
MHz, DMSO-d6) δ 172.5, 169.6, 158.9, 152.7, 148.6, 139.3, 134.2, 132.5, 
128.6, 128.2, 126.7, 124.9, 109.2, 62.8, 45.1, 13.2. ESI-MS: m/z443 
(M+1) observed for C20H16 ClN5O3S.
3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-5-(thiophen-2-yl)-
4,5-dihydro-1H-pyrazole-1-carbothioamide (5h)
Yield 74%, mp 104–112°C. IR spectrum, ν, cm−1:3348, 2993, 1520, 
1404, 1348, 1095. 1H NMR (400 MHz, DMSO-d6) δ 2.7 (s, 3H, CH3), 
3.1 (dd, 1H, CH2), 4.0 (dd, 1H, CH2), 6.0 (td, 1H, -CH), 6.9–7.4 (m, 
3H, ArH), 7.7 (s, 1H, NH2), 7.8–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2). 13C 
NMR (100 MHz, DMSO-d6) δ171.8, 169.8, 158.9, 152.4, 148.5, 138.3, 
135.5, 128.4, 127.5, 126.5, 126.0, 123.6, 121.5, 109.3, 62.3, 45.0, 13.1. 
ESI-MS: m/z414 (M+1) observed for C18H15N5O3S2.
5-(furan-2-yl)-3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-4,5-
dihydro-1H-pyrazole-1-carbothioamide(5i)
Yield 71%, mp 105–118°C. IR spectrum, ν, cm−1: 3346, 2925, 1520, 
1404, 1348, 1095. 1H NMR (400 MHz, DMSO-d6) δ 2.60 (s, 3H, CH3), 3.0 
(dd, 1H, CH2), 4.0 (dd, 1H, CH2), 6.0 (td, 1H, -CH), 6.8–7.4 (m, 3H, ArH), 
7.6 (s, 1H, NH2), 7.9–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2). 13C NMR (100 
MHz, DMSO-d6) δ171.8, 169.2, 158.9, 152.7, 150.8, 148.5, 142.4, 135.5, 
126.5, 123.6, 112.6, 113.9, 109.3, 60.1, 42.1, 13.1. ESI-MS: m/z398 
(M+1) observed for C18H15N5O4S.
5-(4-methoxyphenyl) -N-methyl-3-(5-methyl-3-(4-nitrophenyl) 
isoxazol-4-yl) -4,5-dihydro-1H-pyrazole-1-carbothioamide (5j)
Yield 68%, mp 124–132°C. IR spectrum, ν, cm−1: 3337, 2927, 1525, 
1348, 1404, 1095, 1032. 1H NMR (400MHz, DMSO-d6) δ 2.6 (s,3H,CH3), 
2.8 (s,3H,CH3), 3.0 (dd,1H, CH2), 3.6 (s, 3H, OCH3) 4.0 (dd, 1H, CH2), 6.0 
(td, 1H, -CH), 7.1–7.4 (m, 4H, ArH), 7.7 (s, 1H, NH2), 7.9–8.1 (m, 4H, ArH), 
8.2 (s, 1H, NH2). 13C NMR (100 MHz, DMSO-d6) δ 172.0, 169.1, 162.5, 
158.3, 152.2, 148.7, 138.3, 134.4, 127.8, 127.3, 124.8, 118.4, 109.4, 62.2, 
56.8, 42.7, 31.1 13.1. ESI-MS: m/z451 (M+1) observed for C22H21N5O4S.
5-(4-chlorophenyl)-N-methyl-3-(5-methyl-3-(4-nitrophenyl)
isoxazol-4-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (5k)
Yield 70%, mp 121–123°C. IR spectrum, ν, cm−1: 3339, 2925, 1520, 
1404, 1348, 1095, 750. 1H NMR (400MHz, DMSO-d6) δ 2.6 (s,3H,CH3), 
2.8 (s,3H,CH3), 3.0(dd,1H, CH2), 4.0 (dd, 1H, CH2), 5.9 (td, 1H, -CH), 7.2–
7.5 (m, 4H, ArH), 7.7 (s, 1H, NH2), 7.8–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2). 
13CNMR (100MHz,DMSOd6) δ 171.9, 169.4, 158.3, 152.5, 148.8, 138.6, 
134.5, 132.2, 128.3, 127.5, 126.7, 124.4, 105.7, 62.7, 45.1, 31.4, 13.3. 
ESI-MS: m/z457 (M+1) observed for C21H18 ClN5O3S.
N-methyl-3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-5-phenyl-
4,5-dihydro-1H-pyrazole-1-carbothioamide (5l)
Yield 71%, mp 117–123°C. IR spectrum, ν, cm−1: 3342, 2925, 1521, 
1404, 1346,1095. 1H NMR (400MHz, DMSO-d6) δ 2.5 (s,3H,CH3), 
2.8(s,3H,CH3), 3.1(dd,1H, CH2), 4.0 (dd, 1H, CH2), 5.9 (td, 1H, -CH), 7.1–
7.4 (m, 4H, ArH), 7.7 (s, 1H, NH2), 7.8–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2) 
.13CNMR (100MHz,DMSOd6) δ 172.4, 168.9, 158.4, 152.7, 148.9, 141.1, 
136.2, 128.9, 126.8, 126.2, 124.6, 123.5, 109.2, 62.1, 45.6, 13.0, 31.6. 
ESI-MS: m/z422 (M+1) observed for C21H19N5O3S.
5-(4-bromophenyl)-N-methyl-3-(5-methyl-3-(4-nitrophenyl)
isoxazol-4-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (5m)
Yield 69%, mp 111–117°C. IR spectrum, ν, cm−1: 3340, 2926, 1523, 
1404, 1348, 1093, 670. 1H NMR (400MHz, DMSO-d6) δ 2.6 (s,3H,CH3), 
2.8 (s,3H,CH3), 3.1 (dd,1H, CH2), 3.0 (dd, 1H, CH2), 5.9 (td, 1H, -CH), 7.2–
7.5 (m, 4H, ArH), 7.7 (s, 1H, NH2), 7.8–8.1 (m, 4H, ArH), 8.2 (s, 1H, NH2). 
13CNMR (100MHz,DMSOd6) δ172.5, 168.9, 158.6, 152.3, 148.8, 140.9, 
136.8, 130.9, 128.4, 126.4, 124.7, 122.3, 105.9, 62.4, 42.9, 31.6, 13.4. 
ESI-MS: m/z500 (M+1) observed for C21H18BrN5O3S
5-(4-fluorophenyl)-N-methyl-3-(5-methyl-3-(4-nitrophenyl)
isoxazol-4-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (5n)
Yield 72%, mp 115–120°C. IR spectrum, ν, cm−1: 3344, 2923, 1525, 
1404, 1348, 1096, 1000. 1H NMR (400MHz, DMSO-d6) δ 2.7(s,3H,CH3), 
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2.8 (s,3H,CH3), 3.0(dd,1H, CH2), 4.1 (dd, 1H, CH2), 6.0 (td, 1H, -CH), 7.1–
7.5 (m, 4H, ArH), 7.8 (s, 1H, NH2), 7.9–8.1(m, 4H, ArH), 8.2 (s, 1H, NH2). 
13C NMR (100 MHz, DMSO-d6) δ 171.6, 168.8, 161.4, 158.3, 152.8, 148.9, 
137.4, 134.6, 128.2, 126.7, 125.5, 118.6,109.6, 62.1, 45.0, 31.6,13.1.ESI-
MS: m/z440 (M+1) observed for C21H18 FN5O3S.
N-methyl-3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-5-(p-
tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide (5o)
Yield 69 %, mp 119–125°C. IR spectrum, ν, cm−1: 3340, 2926, 1523, 
1404, 1348, 1093.
1H NMR (400 MHz, DMSO-d6) δ 2.6 (s, 3H, CH3), 2.8 (s, 3H, CH3), 3.1(dd, 
1H, CH2), 4.1(dd, 1H,CH2), 5.9(td, 1H, CH), 7.1–7.5 (m, 4H, ArH), 7.7(s, 
1H, NH2), 7.8–8.1(m, 4H, ArH), 8.2(s,1H,NH2). 13C NMR (100 MHz, 
DMSO-d6) δ172.3, 169.5, 158.2, 152.1, 148.6, 138.5, 136.1, 134.4, 128.2, 
126.5,125.6, 123.3, 109.8, 61.9, 42.8, 31.9, 21.5, 13.1. ESI-MS: m/z436 
(M+1) observed for C22H21N5O3S.
5-(2-chlorophenyl) -N-methyl-3-(5-methyl-3-(4-nitrophenyl) 
isoxazol-4-yl) -4,5-dihydro-1H-pyrazole-1-carbothioamide (5p)
Yield 73%, mp 121–123°C. IR spectrum, ν, cm−1: 3342, 2928, 1523, 
1404, 1348, 1095, 752.
1H NMR (400 MHz, DMSO-d6) δ 2.5 (s, 3H, CH3), 2.7 (s, 3H, CH3), 3.0(dd, 
1H, CH2), 4.1(dd, 1H,CH2), 5.9(td, 1H, CH),7.1-7.5(m, 4H, ArH), 7.6(s, 1H, 
NH2), 7.9–8.1 (m, 4H, ArH), 8.2(s,1H,NH2). δ171. 8, 168.6, 158.2, 152.2, 
148.8, 138.8, 135.2, 131.9, 128.9, 128.1, 126.5, 124.1, 109.8, 62.2, 45.6, 
21.7, 31.2, 13.2. ESI-MS: m/z457 (M+1) observed for C22H21 ClN5O3S.
N-methyl-3-(5-methyl-3-(4-nitrophenyl)isoxazol-4-yl)-5-
(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide(5q)
Yield 72%, mp 105–114°C. IR spectrum, ν, cm−1: 3339, 2927, 1526, 
1404, 1348, 1097.
1H NMR (400 MHz, DMSO-d6) δ 2.6 (s, 3H, CH3), 2.8 (s, 3H, CH3), 3.1(dd, 1H, 
CH2), 3.9(dd, 1H,CH2), 6.0(td, 1H, CH), 6.9–7.4(m, 3H, ArH), 7.8(s, 1H, NH2), 
7.9–8.1(m, 4H, ArH), 8.2(s,1H,NH2 ). ESI-MS: m/z428 (M+1) observed for 
C19H17N5O3S2.δ171.8, 169.8,158.9, 153.9,148.5, 138.7,134.9,128.8,127.9, 
126.8, 126.1, 123.4, 121.4, 109.7, 62.6, 45.4, 13.0.
5-(furan-2-yl)-N-methyl-3-(5-methyl-3-(4-nitrophenyl)isoxazol-
4-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide(5r)
Yield 70%, mp 117–123°C. IR spectrum, ν, cm−1: 3342, 2925, 1521, 
1404, 1346, 1095. 1H NMR (400 MHz, DMSO-d6) δ 2.5(s, 3H, CH3), 
2.8(s.1H.ArH), 3.0 (dd, 1H, CH2), 4.0 (dd, 1H, CH2), 6.0 (td, 1H, -CH), 6.8–
7.4 (m, 3H, ArH), 7.7 (s, 1H, NH2), 7.9–8.1 (m, 4H, ArH), 8.2 (s, 1H,NH2). 
13CNMR(100MHz,DMSO-d6) δ 172.4, 169.5, 158.9, 153.5, 150.2, 148.8, 
142.6, 135.8, 126.3, 123.5, 112.4, 113.7, 109.6, 62.6, 42.6, 31.6, 13.1.ESI-
MS: m/z411 (M+1) observed for C19H17N5O4S.
Docking studies
The molecular docking application is used to interpret the binding 
affinities and interaction modes of synthesized compounds and the target 
protein DHFR implementing the LibDock module of DS. The LibDock 
docking algorithm is a site-featured procedure. The binding site features 
are referred to as “Hot Spots” and that are determined in a grid settled 
inside the active site. This enables the hotspot map count in the active 
site of the protein for a polar and polar cluster that enables considerable 
alignment of the ligand arrangement to protein interaction sites. The 
minimized protein and ligand along with the binding site atom number 
or the X, Y, and Z points of the binding site residue within 12 Å submitted 
to the LibDock setup. All other docking and resultant scoring parameters 
applied were executed at their default settings. Finally, it restores the 
entire minimized ligand poses and their rankings based on the scoring 
function that calculates the binding affinity score or the docking score 
(LibDock score) of the protein-ligand complex. Furthermore, the possible 
binding energies, hydrogen bonding, and various interaction poses 
are calculated. The binding poses were recommended on the criterion 
of LibDock Score rank. Binding poses with the highest LibDock score 
and lowest binding energy are preferred as the best pose and further 
binding interactions of the best pose for each compound are analyzed. 
In addition, the Analyze Ligand Poses subprotocol in DS was applied. To 
ensure the docking method was efficient, docking the standard reference 
drug doxorubicin with the human DHFR binding site is done. The docking 
results are examined in comparison to that of the reference doxorubicin 
in terms of their interactions and docking scores with the protein DHFR.
RESULTS AND DISCUSSION
Chemistry
A series of 5-(substituted phenyl) -3-(5-methyl-3-(4-nitrophenyl) 
isoxazole-4-yl) -4,5-dihydro-1H-pyrazole-1-carbothioamide and 
5-(substituted phenyl) -N-methyl-3-(5-methyl-3-(4-nitrophenyl) 
isoxazole-4-yl) -4,5-dihydro-1H-pyrazole-1-carbothioamide 5 
(a-r) were synthesized in following five steps (Fig. 1). In the first 
step, 4-nitrobenzaldehydeoxime 1 was prepared by the reaction of 
4-nitrobenzaldehyde with hydroxylamine hydrochloride. In the second 
step, 1-(5-methyl-3-(4-nitrophenyl) isoxazole-4-yl) ethanone3 was 
prepared from in situ synthesized N-hydroxy-4-nitrobenzimidoyl 
chloride 2 and acetylacetone in methanol. In the next step, the compound 
3 was condensed with various substituted aromatic aldehydes in the 
presence of NaOH under reflux for 30–50 min to obtain intermediate 
1-(5-methyl-3-(4-nitrophenyl) isoxazole-4-yl) -3-(substituted phenyl) 
prop-2-en-1-one 4 (a-m). In the final step, intermediate 4 (a-m) was 
refluxed with thiosemicarbazides and substituted thiosemicarbazide 
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in potassium hydroxide using ethanol as a solvent for 3–4 h to result 
in 5-(substituted phenyl) -3-(5-methyl-3-(4-nitrophenyl) isoxazole-
4-yl) -4,5-dihydro-1H-pyrazole-1-carbothioamide and 5-(substituted 
phenyl) -N-methyl-3-(5-methyl-3-(4-nitrophenyl) isoxazole-4-yl) 
-4,5-dihydro-1H-pyrazole-1-carbothioamide 5 (a-r) were synthesized 
in quantitative yields in quantitative yields. All the derivatives were 
characterized by 1H NMR, IR, and ESI-MS spectra.
Docking studies
Molecular docking was performed using DHFR protein and synthesized 
compounds 5 (a-r) in LibDock. Different poses were generated for each 
ligand and scored using a LibDock scoring function which estimates their 
equitable LibDock scores with various orientations. Based on the docked 
score, all the compounds were ranked. The docked complex of protein 
and compounds was forming hydrogen bonds and other parameters like 
Van der Waals clashes. Finally, Analyze Ligand Poses subprotocol was 
executed to list out H bonds and close contacts (Van der Waals clashes) 
between docked complexes. The interacting residues were analyzed using 
the receptor-ligand interaction protocol of DS. Table 1 shows the calculated 
binding scores of the compounds inward the human DHFR active site. It 
was observed that out of all compounds, the compound 5b had the highest 
docking score of 144.368  kcal/mol indicating the better binding affinity 
against the target protein human DHFR (1KMS). Fig. 2 shows the three-
dimensional description of proposed binding mode and protein-ligand 
interactions of compound 5b on active site residues of DHFR. From the 
docking analysis of compound 5b with human DHFR, it was recognized 
in view the formation of four hydrogen bonds enclosing the ligand with 
two interacting residues of the binding site. Nitrogen (N25) of compound 
5b formed the hydrogen bond with TYR121 requiring the hydrogen atom 
of the amine group (A: TYR121: HN – 5b: N25) having a hydrogen bond 
distance of 1.908000 Å and an oxygen atom of compound 5b formed the 
hydrogen bond with VAL115 with a hydrogen bond distance of 2.292000 
Table 1: Calculated docking scores, interacting atoms and amino acids and H-bond count of synthesized compounds along with 
reference drug doxorubicin with the human DHFR (1KMS) active site
Name LibDock score Interacting atoms H-bond count
5a 125.036 H45 - A: VAL115:O
H42 - A: VAL8: HG22
3
5b 144.368 H45 - A: VAL115:O
H45 - A: TYR121: OH
H46 - A: TYR121: OH
N25 - A: TYR121: HH
H46 - A: TYR121: HH
N25 - A: TYR121: HH
4
5c 125.036 H48 - A: PRO61: CG
C22 - A: PRO61: HG1
3
5d 126.851 H39 - A: PRO61: HD2
H37 - A: PRO61: HD1
1
5e 134.368 H41 - A: PHE31: HZ
H39 - A: PRO61: HD2
H37 - A: PRO61: HD1
N25 - A: TYR121: HH
H46 - A: TYR121: HH
N25 - A: TYR121: HH
4
5f 134.65 F: H41 - A: VAL115:O
H42 - A: TYR121: OH
N19 - A: TYR121: HH
H42 - A: TYR121: HH
3
5g 132.17 H48 - A: PRO61: CG
C22 - A: PRO61: HG1
1
5h 142.302 H41 - A: VAL115:O
H42 - A: TYR121: OH
N19 - A: TYR121: HH
H42 - A: TYR121: HH
3
5i 134.65 A: TYR121: HH: N8
O9 - A: VAL8: HA
2
5j 128.119 A: TYR121: HH: O9 2
5k 122.242 H39 - A: VAL115:O
A: TYR121: HH - O25
A: VAL8: HG22 - C24
A: VAL8: HG22 - H43
3
5l 124.452 A: TYR121: HH: O9 2
5m 127.339 A: TYR121: HH: O9 2
5n 132.451 A: TYR121: HH: O9 2
5o 132.17 A: PRO61: HD1 -: H38
A: PRO61: HD2 -: H40
1
5p 112.318 H48 - A: PRO61: CG
C22 - A: PRO61: HG1
1
5q 123.995 H39 - A: VAL115 :O
H42 - A: VAL8: HA
C24 - A: VAL8: HG22
2
5r 128.119 A: TYR121: HH: N8
O9 - A: VAL8: HA
2
Doxorubicin 150.181 Glu30, phe34, phe31, ile7, val115, tyr121, val8, pro61 1
250
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Å. There was a single hydrogen bond formation between nitrogen (N25) 
atom of compound 5b and a hydrogen atom (HH) of TYR121 (A: TYR121: 
HH – 5b: N25) with a hydrogen bond distance of 1.681000 Å. A hydrogen 
bond is formed when the hydrogen atom of VAL115b interacted with the 
oxygen atom of the compound 5b (A: VAL115: O-H45-5b) with a hydrogen 
bond distance of 2.465000 Å. Another hydrogen bond is formed between 
a hydrogen atom of TYR121 and the oxygen atom of the compound 5b (A: 
TYR121: H45 – 5b: OH) with a hydrogen bond distance of 2.292000 Å. 
Some non-bonded interactions are in the docking validation; the reference 
drug doxorubicin was docked into the binding site of human DHFR. The 
binding affinities of the synthetic compounds were compared and analyzed 
in reference to doxorubicin. An accurate analysis of the docking scores and 
interactions in comparison with that of reference reveals that the docked 
ligands were found to have similar binding poses with good and moderate 
scores, thus validating the adopted docking methodology. Herein, the best-
scored compound 5b (144.368) exhibited relatively comparable binding 
score with appropriate confirmation that is very close to the reference 
doxorubicin (150.181 l), hence, showing better binding affinity.
Cytotoxic activity
The title compounds were evaluated for an antiproliferative activity 
through MTT ([3-(4, 5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium 
bromide]) based cytotoxic assay against MCF-7 breast cancer cell 
line with Taxol as standard reference and results were summarized 
in Table 2. All tested compounds have shown significant cytotoxic 
activity. Among all the tested compounds 5a, 5b, 5f, 5h, and 5k exhibited 
significant percentage inhibition of cell proliferation at an IC50 value of 
4.480 µg/ml, 5.452 µg/ml, 4.215 µg/ml, 2.253 µg/ml, and 4.982 µg/ml.
CONCLUSIONS
The results of the present study demonstrated the synthesis of 
pyrazoline incorporated isoxazole derivatives and in silico evaluation for 
their efficacy as anticancer compounds through docking against hDHFR. 
Compound 5b is recognized as the most hopeful anticancer compound 
among the synthesized derivatives based on its highest docking score 
assuming the higher selective basis for hDHFR protein The synthesized 
compounds were evaluated the cytotoxic activity, compounds 5a, 5b, 5f, 
5h, and 5k exhibited significant activity. Thus, the present study proposed 
the compounds 5b as the best effective inhibitor of human DHFR protein 
with significant anticancer activity and brings forth a new root line in 
designing inhibitors in the drug discovery process to treat cancer.
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